You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 829 A potent STING agonist in combination with a novel anti-PD-L1/PD-L2 antibody leads to significant tumor responses in checkpoint-refractory cancers

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
829 A potent STING agonist in combination with a novel anti-PD-L1/PD-L2 antibody leads to significant tumor responses in checkpoint-refractory cancers

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023188019
Dec 20233806
Jan 20242102
Feb 20242401
Mar 202442010
Apr 20244003
May 20243403
Jun 202476011
Jul 202456011
Aug 20243804
Sep 20243203
Oct 20243007
Nov 202430010
Dec 202442011
Jan 20255007
Feb 20251003
Mar 20250011
Apr 2025001
May 2025004
Jun 20251104
Total7620131